Journal of the American Academy of Dermatology

The most recent articles from: J. Am. Acad. Dermatol. July 2021

J. Am. Acad. Dermatol. · Jul 2021

Randomized Controlled Trial Multicenter Study

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).

Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. ⋯ Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.

read on… or not…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!